MedTrace Logo

WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia

NCT02603536 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2017-02-02

No results posted yet for this study

Summary

WelTel Oak Tree is a repeated measures study that enrolled 85 HIV+ individuals from the Oak Tree Clinic at BC Women's Hospital. Participants were be provided with a cell phone and/or unlimited text messaging capability if they do not have it already, and for one year received a weekly text message stating "How are you". Participant problems and non-responses were be followed up by a nurse. Data on demographics, CD4 counts, HIV viral loads, HIV medication adherence and attendance at appointments was collected for the year prior to the intervention and during the intervention for comparison. Data assessing quality of life was also collected at three points during the one year study period. Cost effectiveness and cost benefit of the intervention is being studied to assess feasibility of transferring the intervention to a programmatically funded facet of patient care.

Conditions

  • HIV
  • Medication Adherence

Interventions

OTHER

WelTel

An evidence-based, text messaging solution for improving patient adherence.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • BC Women's Hospital & Health Centre

    lead OTHER

Principal Investigators

  • Melanie Murray, MD,PhD,FRCPC · BC Women's Hospital & Health Centre

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-05-31
Completion
2016-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02603536 on ClinicalTrials.gov